Merck, Illumina back immune-mapper SerImmune in $8M round by Amirah Al Idrus Tuesday, June 20, 2017 SerImmune, whose technology maps the human antibody repertoire, rounded up $8 million from Merck, Illumina Ventures and unnamed investors.
